Douglas J. Hughes insider trades
Open-market stock purchases and sales by Douglas J. Hughes, Director at Immunovant, Inc, from SEC Form 4 filings since Dec 18, 2019.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +253%.